INNOVA CAPTAB LIMITED
INNOVACAP · General/Diversified · NSE
₹947
Current Market Price
Under Review— We don’t have enough data to publish a fair value estimate for INNOVACAP yet. Reason: Data Limited.
Updated just now
YieldIQ Score
—
Piotroski F-Score
7/9
Economic Moat
Narrow
Confidence
19%
ROE
12.9%
Debt/Equity
0.32
WACC
11.1%
Market Cap
₹5,421 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
17.4%
Return on capital employed
EV / EBITDA
21.2×
Enterprise multiple
Debt / EBITDA
1.4×
Leverage vs earnings
Interest Coverage
77.3×
EBIT covers interest
Current Ratio
1.99×
Short-term liquidity
Asset Turnover
1.03×
Revenue per ₹ of assets
Revenue CAGR (3Y)
20.1%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
Ratio Trends
INNOVACAP · last 5 annual periods
ROE
12.9%
ROCE
17.4%
Operating Margin
—
Debt / Equity
0.32×
PE
—
EV / EBITDA
—
Historical Financials
INNOVACAP · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 yfinance | 2023 yfinance | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹800 Cr | ₹925 Cr | ₹1077 Cr | ₹1234 Cr | ₹1604 Cr | +19.0% |
| EBITDA | ₹98.5 Cr | ₹122 Cr | ₹167 Cr | ₹198 Cr | ₹250 Cr | +26.2% |
| EBIT | — | — | ₹151 Cr | — | — | +0.0% |
| PAT | ₹64.0 Cr | ₹68.0 Cr | ₹94.3 Cr | ₹128 Cr | ₹141 Cr | +21.8% |
| EPS (diluted) | — | — | ₹18.66 | — | — | +0.0% |
| CFO | ₹58.9 Cr | ₹67.1 Cr | ₹146 Cr | ₹63.8 Cr | ₹117 Cr | +18.6% |
| CapEx | ₹-79.9 Cr | ₹-79.0 Cr | ₹-287 Cr | ₹-172 Cr | ₹-68.4 Cr | — |
| FCF | ₹-21.0 Cr | ₹-11.9 Cr | ₹-141 Cr | ₹-109 Cr | ₹48.2 Cr | — |
| Total Assets | ₹575 Cr | ₹704 Cr | ₹1321 Cr | ₹1580 Cr | ₹1837 Cr | +33.7% |
| Total Debt | ₹199 Cr | ₹237 Cr | ₹245 Cr | ₹338 Cr | ₹344 Cr | +14.6% |
| Shareholders' Equity | ₹209 Cr | ₹277 Cr | ₹831 Cr | ₹959 Cr | ₹1091 Cr | +51.2% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
INNOVACAP vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
SPARC SPARC | — | — | Pending | 157.9% | — |
GUJTHEM GUJTHEM | — | — | Pending | 16.2% | — |
 AARTIDRUGS AARTI DRUGS LTD. | -5.5%-5.2% upside | 51 | Near Fair Value | 13.4% | 15.0× |
 RPGLIFE RPG LIFE SCIENCES LTD | -113.7%-53.2% upside | 40 | Above Fair Value | 20.3% | — |
 GUFICBIO GUFICBIO | — | — | Pending | 9.7% | 42.8× |
Click a ticker to view its fair-value analysis.
Dividend History
1 ex-dividend event on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹2.00/sh
Last payout
2026-01-30
₹2.00
Peak payout
₹2.00
Trailing yield
0.21%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
Risk Analysis
Volatility & drawdown
Risk profile of INNOVACAP →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for INNOVACAP →
Compare
Head-to-head with peers
Compare INNOVACAP side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse INNOVACAPNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.